

Accelerating Development of Better PTSD Treatment for Veterans: VA's PTSD Psychopharmacology Initiative (PPI)



VA medical centers nationwide; currently includes San Francisco, San Diego, Seattle, West Haven, National Center for PTSD, Tuscaloosa, Durham

Why this research is important:

A critical medical need has been identified in that there are only two FDA-approved medications for PTSD. While these medications are effective in some veterans with PTSD, they are not uniformly successful in managing symptoms for every Veteran with PTSD. We need to identify and test new medications to expand treatment capabilities and reduce PTSD symptoms.

Summary:

The PTSD Psychopharmacology Initiative (PPI) effort was launched in 2016 following a review of PTSD medications and ongoing trials. At the time only two clinical trials were underway, and potential new compounds had not been identified. Since the launch of the PPI, VA Research has held an industry day to work with new pharmaceutical partners, conducted a training workshop for VA clinician scientists, and launched an additional four clinical trials. The goal is to identify and test 12 new medications for PTSD by 2020 through continued extensive partnership and focus on this important Veterans healthcare need.

How the research will improve Veterans' lives:

This initiative should directly impact Veterans' lives by identifying and testing new and better medications to treat PTSD.



Dr. Thomas Neylan



U.S. Department of Veterans Affairs

Veterans Health Administration
Office of Research & Development